28503759|t|Evaluation of Weight Change During Carboplatin Therapy in Dogs With Appendicular Osteosarcoma
28503759|a|The prevalence of cancer cachexia in veterinary medicine has not been studied widely, and as of yet, no definitive diagnostic criteria effectively assess this syndrome in veterinary patients. (1) To determine the patterns of weight change in dogs with appendicular osteosarcoma treated with amputation and single-agent carboplatin during the course of adjuvant chemotherapy; and (2) to determine whether postoperative weight change is a negative prognostic indicator for survival time in dogs with osteosarcoma. Eighty-eight dogs diagnosed with appendicular osteosarcoma. Animals were accrued from 3 veterinary teaching hospitals. Retrospective, multi-institutional study. Dogs diagnosed with appendicular osteosarcoma and treated with limb amputation followed by a minimum of 4 doses of single-agent carboplatin were included. Data analyzed in each patient included signalment, tumor site, preoperative serum alkaline phosphatase activity (ALP), and body weight (kg) at each carboplatin treatment. A slight increase in weight occurred over the course of chemotherapy, but this change was not statistically significant. Weight change did not have a significant effect on survival. Institution, patient sex, and serum ALP activity did not have a significant effect on survival. Weight change was not a prognostic factor in these dogs, and weight loss alone may not be a suitable method of determining cancer cachexia in dogs with appendicular osteosarcoma.
28503759	0	10	Evaluation	T058	C0220825
28503759	14	27	Weight Change	T033	C0005911
28503759	35	54	Carboplatin Therapy	T061	C2960156
28503759	58	62	Dogs	T015	C1280551
28503759	68	80	Appendicular	T023	C0003617
28503759	81	93	Osteosarcoma	T191	C0029463
28503759	98	108	prevalence	T081	C0220900
28503759	112	127	cancer cachexia	T191	C1391732
28503759	131	150	veterinary medicine	T091	C0042615
28503759	164	171	studied	T062	C2603343
28503759	209	228	diagnostic criteria	T170	C0679228
28503759	241	247	assess	T058	C0184514
28503759	253	261	syndrome	T047	C0039082
28503759	265	284	veterinary patients	T001	C1705908
28503759	307	315	patterns	T080	C1272746
28503759	319	332	weight change	T033	C0005911
28503759	336	340	dogs	T015	C1280551
28503759	346	358	appendicular	T023	C0003617
28503759	359	371	osteosarcoma	T191	C0029463
28503759	372	379	treated	T169	C1522326
28503759	385	395	amputation	T061	C0002688
28503759	400	424	single-agent carboplatin	T109,T121	C0079083
28503759	436	442	course	T079	C0750729
28503759	446	467	adjuvant chemotherapy	T061	C0085533
28503759	498	511	postoperative	T079	C0032790
28503759	512	525	weight change	T033	C0005911
28503759	531	539	negative	T033	C0205160
28503759	540	560	prognostic indicator	T201	C1514474
28503759	565	578	survival time	T201	C2919552
28503759	582	586	dogs	T015	C1280551
28503759	592	604	osteosarcoma	T191	C0029463
28503759	619	623	dogs	T015	C1280551
28503759	624	633	diagnosed	T033	C0011900
28503759	639	651	appendicular	T023	C0003617
28503759	652	664	osteosarcoma	T191	C0029463
28503759	666	673	Animals	T008	C0003062
28503759	694	723	veterinary teaching hospitals	T073,T093	C0019994
28503759	725	738	Retrospective	T062	C0035363
28503759	740	765	multi-institutional study	T062	C1096776
28503759	767	771	Dogs	T015	C1280551
28503759	772	781	diagnosed	T033	C0011900
28503759	787	799	appendicular	T023	C0003617
28503759	800	812	osteosarcoma	T191	C0029463
28503759	817	824	treated	T169	C1522326
28503759	830	845	limb amputation	T061	C0002689
28503759	873	878	doses	T081	C0178602
28503759	882	906	single-agent carboplatin	T109,T121	C0079083
28503759	922	926	Data	T078	C1511726
28503759	927	935	analyzed	T062	C0936012
28503759	944	951	patient	T001	C1705908
28503759	961	971	signalment	T080	C0205556
28503759	973	983	tumor site	T082	C0475445
28503759	985	997	preoperative	T079	C0445204
28503759	998	1003	serum	T031	C0229671
28503759	1004	1033	alkaline phosphatase activity	T044	C1149888
28503759	1035	1038	ALP	T044	C1149888
28503759	1045	1056	body weight	T032	C0005910
28503759	1070	1081	carboplatin	T109,T121	C0079083
28503759	1082	1091	treatment	T169	C0039798
28503759	1095	1110	slight increase	T169	C0442805
28503759	1114	1120	weight	T032	C0005910
28503759	1139	1145	course	T079	C0750729
28503759	1149	1161	chemotherapy	T061	C3665472
28503759	1172	1178	change	T033	C0005911
28503759	1187	1212	statistically significant	T081	C0237881
28503759	1214	1227	Weight change	T033	C0005911
28503759	1243	1261	significant effect	T080	C1280500
28503759	1265	1273	survival	T169	C0220921
28503759	1288	1299	patient sex	T032	C0150831
28503759	1305	1310	serum	T031	C0229671
28503759	1311	1323	ALP activity	T044	C1149888
28503759	1339	1357	significant effect	T080	C1280500
28503759	1361	1369	survival	T169	C0220921
28503759	1371	1384	Weight change	T033	C0005911
28503759	1395	1412	prognostic factor	T201	C1514474
28503759	1422	1426	dogs	T015	C1280551
28503759	1432	1443	weight loss	T033	C1262477
28503759	1472	1478	method	T170	C0025663
28503759	1494	1509	cancer cachexia	T191	C1391732
28503759	1513	1517	dogs	T015	C1280551
28503759	1523	1535	appendicular	T023	C0003617
28503759	1536	1548	osteosarcoma	T191	C0029463